HUYA Bioscience International
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HUYA Bioscience International
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.
Joining a growing number of its multinational peers tapping into China’s expanding innovative capabilities, Boehringer Ingelheim has teamed up with an academic research group to develop novel stem cell therapies for hearing loss, further encouraged by new state support for regenerative medicine.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Specialty Pharmaceuticals